Question 62

Ventolin HFA and Xopenex HFA represent therapeutic duplication concerns.

Using both Ventolin HFA and Xopenex HFA can lead to therapeutic duplication as both medications are short-acting bronchodilators used for the relief of asthma symptoms. Prescribing them simultaneously may increase the risk of side effects without providing additional therapeutic benefit.

A) Spiriva Respimat and Dulera.

Spiriva Respimat is a long-acting anticholinergic, while Dulera is a combination inhaler containing a long-acting beta-agonist and a corticosteroid. These medications serve different mechanisms and purposes in asthma management, thus not representing therapeutic duplication.

B) Flovent HFA and Incruse Ellipta.

Flovent HFA is an inhaled corticosteroid whereas Incruse Ellipta is a long-acting anticholinergic. These two medications are used to manage asthma and COPD symptoms but do not duplicate therapy as they target different aspects of airway inflammation and bronchoconstriction.

C) Ventolin HFA and Xopenex HFA.

Both Ventolin HFA and Xopenex HFA are short-acting beta-agonists used for the quick relief of asthma symptoms. Prescribing these together poses a risk of therapeutic duplication, as they essentially provide the same clinical effect and may lead to unnecessary side effects.

D) Serevent Diskus and Atrovent HFA.

Serevent Diskus is a long-acting beta-agonist, and Atrovent HFA is an anticholinergic. Although they both help manage respiratory conditions, they do not duplicate therapy since they work through different pharmacological pathways.

Conclusion

The concern for therapeutic duplication is most prevalent with Ventolin HFA and Xopenex HFA, as both are short-acting beta-agonists providing similar effects. The other options involve medications that serve different roles in treatment, thereby avoiding duplication of therapy. This distinction is critical in ensuring optimal patient care and minimizing unnecessary medication use.